Pre-ERCP High Carbohydrate Drinks Improve Patients Recovery

Pre-ERCP Carbohydrate Drinks Improve Patients Recovery: an ERAS Protocol Attempts in ERCP

To test the benefits of extra high carbohydrate liquid diet uptake 2 hours before ERCP in improving patients' early recovery.

Study Overview

Status

Completed

Conditions

Detailed Description

Enhanced recovery after surgery (ERAS) has been formed of procedure which contains preoperative education, improvement of anesthesia, reducing the number of drainage tubes, and early diet after surgery. In recent years, because of its positive advantages, ERAS was widely accepted in surgical fields.

For upper gastrointestinal surgery, high-carbohydrate drinks can be given 2 hours before surgery in order to guarantee the stability of blood glucose and circulation during the operation. It obviously reduce the preoperative thirst, hunger, irritability and even the incidence of postoperative complications.

However ERAS program is rarely studied in ERCP. Theoretically we can use ERAS as a strategy to reduce post-ERCP uncomfortable and complications.

Study Type

Interventional

Enrollment (Actual)

1292

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Chongqing
      • Chongqing, Chongqing, China, 400038
        • Third Military Medical University
    • Gansu
      • Lanzhou, Gansu, China, 730000
        • The First Hospital of Lanzhou University
    • Guangdong
      • Guangzhou, Guangdong, China, 510260
        • The Second Affiliated Hospital of Guangzhou Medical University
    • Hebei
      • Shijiazhuang, Hebei, China, 050000
        • The Second Hospital of Hebei Medical University
    • Hubei
      • Wuhan, Hubei, China, 430022
        • Tongji medical collage,Huazhong University of science and technology
    • Hunan
      • Changsha, Hunan, China, 410011
        • Second Xiangya Hospital, Central South University
    • Jilin
      • Changchun, Jilin, China, 130021
        • The First Hospital of Jilin University
    • Ningxia
      • Yingchuan, Ningxia, China, 750004
        • General Hospital of Ningxia Medical University
    • Shaanxi
      • Xi'an, Shaanxi, China, 710061
        • The First Affiliated Hospital of Xi 'An Jiaotong University
    • Shandong
      • Jinan, Shandong, China, 250000
        • Shandong jiaotong Hospital
    • Shanghai
      • Shanghai, Shanghai, China, 200092
        • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    • Shanxi
      • Taiyuan, Shanxi, China, 030008
        • Taiyuan Iron and Steel Corporation Hospital
    • Tianjin
      • Tianjin, Tianjin, China, 300100
        • Tianjin Nankai Hospital
    • Xinjiang
      • Ürümqi, Xinjiang, China, 830054
        • The First Teaching Hospital of Xinjiang Medical University
    • Zhejiang
      • Hangzhou, Zhejiang, China, 310003
        • Shulan Hospital of Zhejiang University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • ERCP patients,
  • Age 18-85 years old.

Exclusion Criteria:

  • Coagulation dysfunction (INR> 1.3) and low peripheral blood platelet count(<50×109 / L) or using anti-coagulation drugs,
  • Preoperative coexistent diseases: acute pancreatitis, GI tract hemorrhage, severe liver disease, shock, liver or kidney malfunction,
  • Diabetes(blood glucose fluctuations)or with complications,
  • Intestinal obstruction or other contraindications with feeding and watering,
  • Prior surgery of Bismuth Ⅱ and Roux-en-Y,
  • Pregnant women,
  • Unwillingness or inability to consent for the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High carbohydrate liquid diet
No need preoperative fasting more than 6 hours. Uptake 400ml high carbohydrate liquid diet 2 hours before ERCP.
400ml high carbohydrate liquid diet uptake 2 hours before ERCP
Other Names:
  • Routine ERCP
No Intervention: Routine ERCP group
Preoperative fasting more than 6 hours as usual.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Levels of fatigue (Fatigue Scale-14 scoring system)
Time Frame: 6 months
The patients always feel tired and faint. The clinical manifestation includes slow to respond, the flexibility and coordination disorders.
6 months
Abdominal pain
Time Frame: 6 months
Pain score (scores:1-10)
6 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The average incubation time
Time Frame: 6 months
The time of total procedure
6 months
Successful cannulation time
Time Frame: 6 months
From first achieve the papilla to success cannulation
6 months
Postoperative abdominal distention
Time Frame: 6 months
Distention uncomfortable
6 months
Postoperative nausea and vomiting
Time Frame: 6 months
Nausea or vomiting after procedure
6 months
Complications
Time Frame: 6 months
Pancreatitis, cholangitis, bleeding, aspiration, et,al.
6 months
Blood glucose
Time Frame: 6 months
Intra-operative blood glucose and 2 hours' blood glucose after procedure
6 months
Intraoperative residues in stomach
Time Frame: 6 months
The volume of stomach residues
6 months
The time eating
Time Frame: 6 months
The time of eager to eat after procedure
6 months
Length of hospital stay
Time Frame: 6 months
Days of hospital stay
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Xun Li, M.D., Ph. D., Hepatopancreatobiliary Surgery Institute of Gansu Province

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2017

Primary Completion (Actual)

April 17, 2021

Study Completion (Actual)

April 17, 2021

Study Registration Dates

First Submitted

March 4, 2017

First Submitted That Met QC Criteria

March 8, 2017

First Posted (Actual)

March 9, 2017

Study Record Updates

Last Update Posted (Actual)

August 9, 2022

Last Update Submitted That Met QC Criteria

August 7, 2022

Last Verified

August 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

  • HSIGansu

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Complication

Clinical Trials on 400ml high carbohydrate liquid diet before ERCP

Subscribe